Hi-Tech Pharmacal reports profits up 41%

Amityville-based Hi-Tech Pharmacal headquarters on Sept. 10, 2012.

Amityville-based Hi-Tech Pharmacal headquarters on Sept. 10, 2012. Photo Credit: Steve Pfost

advertisement | advertise on newsday

Hi-Tech Pharmacal Co. Inc. Tuesday reported its profit rose 41 percent in the November-January period compared with a year earlier, even as sales of a signature nasal spray dropped.

The Amityville-based drugmaker said its profit for the three months ended Jan. 31 was $8.4 million, compared with $6 million a year earlier.

Sales in Hi-Tech's fiscal third quarter fell 7 percent to $60 million from the same period in fiscal 2013.

Much of the decline came from fluticasone propionate, a generic version of the Flonase nasal spray used to treat sinus ailments. Its sales dropped to $11 million from $23 million a year ago.

The company brought in more money from its brand-name drugs, including the cold medicine TussiCaps, by charging more. Revenue from brand-name products rose 58 percent in the quarter to $8 million.

Hi-Tech also said it expects its sale to another drugmaker, Akorn Inc. of Lake Forest, Ill., to be completed next month. The $640-million deal was announced in August.

Hi-Tech has 447 employees, about 400 locally. Akorn, which produces TheraTears eye medicine and is based in a Chicago suburb, has nearly 1,000 workers, including more than 200 at a subsidiary in India.

advertisement | advertise on newsday

In a conference call with analysts last year, Akorn officials estimated the Hi-Tech purchase would create a company with sales of more than $500 million per year. They also said Hi-Tech has manufacturing capabilities that Akorn lacks, and a planned expansion of Akorn's Somerset, N.J., factory could be shelved because of the deal.

In trading Tuesday on the Nasdaq stock market, Hi-Tech shares were down 0.14 percent to $43.28.

The latest LI business news in your inbox daily. Get the Biz Briefing newsletter!


Newsday.com now uses Facebook for our comment boards. Please read our guidelines and connect your Facebook account to comment.

You also may be interested in: